Please login to the form below

pancreatic cancer

This page shows the latest pancreatic cancer news and features for those working in and with pharma, biotech and healthcare.

Lilly’s pegilodecakin fails in long-shot pancreatic cancer trial

Advanced pancreatic cancer is notoriously hard to treat, and Eli Lilly’s pegilodecakin has joined the list of drugs unable to improve survival compared to standard chemotherapy. ... Pancreatic cancer is currently the seventh leading cause of cancer

Latest news

Sumitomo Dainippon goes big on biotech with $3bn Roivant deal

The stakes are even higher for Sumitomo, following the failure of napabucasin, a potential pancreatic cancer candidate it acquired from Boston Biomedical, earlier this year.
Trial backs role for Lynparza in second-line prostate cancer

It already has approval for ovarian and breast cancer and has also shown a benefit in late-stage data in pancreatic cancer, again the first in its class to do so. ... Prostate cancer is the second-most common cancer in men, with an estimated 1.3
Lynparza cleared as ovarian cancer maintenance therapy on Cancer Drugs Fund

Around 22% of ovarian cancer patients carry a BRCA mutation, which must be identified via a companion diagnostic test. ... breast cancer, and has new indications in pancreatic cancer and prostate cancer in its sights.
BioNTech raises €290m for mRNA cancer vaccine platform

BioNTech was the first biotech to bring an mRNA-based individualised cancer vaccine targeting neoantigens into clinical trials. ... In May, it acquired the antibody assets of US biotech MabVax Therapeutics, headed by an anti-SLea drug called MVT-5873
Pfizer’s Talzenna cleared for breast cancer in Europe

Daurismo (glasdegib) for acute myeloid leukaemia, and Vizimpro (dacomitinib) for locally advanced or metastatic EGFR-positive non-small cell lung cancer (NSCLC). ... The Array deal will give Pfizer control of a Talzenna/Mektovi combination in trials for

More from news
Approximately 24 fully matching, plus 109 partially matching documents found.

Latest Intelligence

Leading AstraZeneca’s return to growth in Europe

the only PARP inhibitor with positive phase 3 results in four different cancer types (ovarian, breast, pancreatic and prostate). ... First we had ovarian cancer, then breast cancer, and our next steps will be for metastatic pancreatic cancer and men with
Cancer immunotherapy: What's on the horizon?

13 new targeted medicines that block the growth and spread of cancer by interfering with specific molecular targets. ... and ovarian cancer, and some tumours such as pancreatic and prostate cancers have proved resistant to current immunotherapies.
Finding the patient voice

Mr Whitley took part in a pancreatic cancer drug trial in 2011.
Deal Watch February 2017

triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer. . ... Licence. 358. AstraZeneca/ TerSera Therapeutics. Zoladex, goserelin acetate implant for prostate, breast cancer,
Deal Watch table for September 2014

1. MM-398 a nanoliposomal irinotecan injection of for metastatic pancreatic cancer in phase III. ... 805. Curevac / Boehringer Ingelheim. Licence and collaboration. Messenger RNA vaccine (CV9202) in combination with afatininib and chemo-radiation for

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest appointments

Celgene names general manager for UK and Ireland

This is even more pertinent with the recent changes to the Cancer Drugs Fund, which I strongly hope will enable patients with myeloma and metastatic pancreatic cancer to continue to be

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Parachuting Behind Enemy Lines: OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)

introduction of multiple localized and targeted therapies in recent years, 2 more than 30, 000 patients succumbed to liver cancer.1 The situation for pancreatic cancer is even more urgent. ... Accessed March 5, 2019. Balaban EP, Mangu PB, Yee NS. Locally
Putting our mission into practice: Porterhouse Medical’s charity round-up 2018 - 2019

The Porterhouse team has also raised funds for Pancreatic Cancer UK (); the ovarian cancer support charity Ovacome (); and the disability sports club SportsAble (). We are delighted to reveal that our team
Creative review: ESMO 2018

This year’s theme focused on securing access to optimal cancer care – a poignant topic and one that resonates across the healthcare sector, impacting patients in all walks of life. ... Ipsen Group developed an eye-catching attraction to offset this
Porterhouse Medical is raising awareness for pancreatic cancer, here’s why…

44 (0) 118 913 9100. Address:. 4 Windsor Square. Silver Street. Reading. RG1 2TH. United Kingdom.
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer

5]. In spite of these statistics, funding for pancreatic cancer and disease awareness are low. ... Indeed, in one analysis, only 75% of patients with localised pancreatic cancer underwent surgical evaluation.